MedTrace Logo

Efficacy of Laflavon in Lowering Triglycerides and Raising High-Density Lipoprotein (HDL)

NCT01286909 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2011-02-10

No results posted yet for this study

Summary

A trial of LaFlavon in Patients with Metabolic Syndrome to Evaluate its Effectiveness in Lowering Triglycerides and Raising High-Density Lipoprotein (HDL).

Conditions

  • Metabolic Disease

Interventions

DIETARY_SUPPLEMENT

LaFlavon

two tablets of LaFlavon (two x 3.5mg lycopene/25 mg soy isoflavone) daily for three months

Sponsors & Collaborators

  • Omicron Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Dr. Akram Echtay, M.D. · Rafic Hariri University Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2011-06-30
Completion
2011-06-30

Countries

  • Lebanon

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01286909 on ClinicalTrials.gov